Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phenomenology of and Risk Factors for New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated with Atypical Antipsychotics: An Analysis of 45 Published Cases

Phenomenology of and Risk Factors for New-Onset Diabetes Mellitus and Diabetic Ketoacidosis... Case reports and small retrospective studies suggest that atypical antipsychotic agents may be associated with new-onset Type II diabetes mellitus (DM) or diabetic ketoacidosis (DKA); however, these reports often provide limited or no information on demographic variables such as age, gender, ethnicity, relationship to weight gain, and time course. We analyzed 45 published cases of new-onset DM or DKA for which followed initiation of atypical antipsychotic treatment. Of the 45 patients, 20 had received clozapine, 19 olanzapine, 3 quetiapine, and 3 risperidone. Eighty-seven percent patients were male, and 47% African American. Forty-two percent of these patients presented as DKA, and 50% manifested no weight gain at time of presentation with DM or DKA, although 84% were overweight before antipsychotic therapy. Eighty-four percent presented within 6 months and 59% within 3 months of commencing atypical antipsychotics. The DKA cohort had significantly younger age, less overweight at baseline, and higher proportion of women than did those with DM alone, without significant differences in distribution of ethnicity, weight gain, family history of DM, or duration of exposure to atypical agents. Clinicians should be aware of the potential risks of new-onset DM and DKA in patients taking atypical antipsychotics, and utilize appropriate clinical and laboratory monitoring to prevent serious adverse events. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Phenomenology of and Risk Factors for New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated with Atypical Antipsychotics: An Analysis of 45 Published Cases

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/phenomenology-of-and-risk-factors-for-new-onset-diabetes-mellitus-and-20bOS9XbHZ
Publisher
Springer Journals
Copyright
Copyright © 2002 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1015228112495
Publisher site
See Article on Publisher Site

Abstract

Case reports and small retrospective studies suggest that atypical antipsychotic agents may be associated with new-onset Type II diabetes mellitus (DM) or diabetic ketoacidosis (DKA); however, these reports often provide limited or no information on demographic variables such as age, gender, ethnicity, relationship to weight gain, and time course. We analyzed 45 published cases of new-onset DM or DKA for which followed initiation of atypical antipsychotic treatment. Of the 45 patients, 20 had received clozapine, 19 olanzapine, 3 quetiapine, and 3 risperidone. Eighty-seven percent patients were male, and 47% African American. Forty-two percent of these patients presented as DKA, and 50% manifested no weight gain at time of presentation with DM or DKA, although 84% were overweight before antipsychotic therapy. Eighty-four percent presented within 6 months and 59% within 3 months of commencing atypical antipsychotics. The DKA cohort had significantly younger age, less overweight at baseline, and higher proportion of women than did those with DM alone, without significant differences in distribution of ethnicity, weight gain, family history of DM, or duration of exposure to atypical agents. Clinicians should be aware of the potential risks of new-onset DM and DKA in patients taking atypical antipsychotics, and utilize appropriate clinical and laboratory monitoring to prevent serious adverse events.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 10, 2004

References

  • Conventional vs. newer antipsychotics in elderly patients
    Jeste, DV; Rockwell, E; Harris, MJ; Lohr, JB; Lacro, J
  • Psychopharmacology from chlorapromazine to olanzapine: A brief history of antipsychotics
    Meyer, JM; Simpson, GM
  • Differential effect of clozapine on weight: A controlled study
    Bustillo, JR; Buchanan, RW; Irish, D; Breier, A
  • Olanzapine-induced weight gain
    Gupta, S; Droney, T; Al-Samarrai, S; Keller, P; Frank, B
  • Novel antipsychotics: Comparisons of weight gain liabilities
    Wirshing, DA; Wirshing, WC; Kysar, L; Berisford, MA; Goldstein, D; Pashdag, J; Mintz, J; Marder, SR
  • Mechanisms of antipsychotic-induced weight gain
    McIntyre, RS; Mancini, DA; Basile, VS
  • Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
    Hagg, S; Joelsson, L; Mjorndal, T; Spigset, O; Oja, G; Dahqvist, R
  • Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
    Henderson, DC; Cagliero, E; Gray, C; Nasrallah, RA; Hayden, DL; Schoenfeld, DA; Goff, DC
  • New onset diabetes and atypical antipsychotics
    Liebzeit, KA; Markowitz, JS; Caley, CF
  • Clozapine-associated elevation in serum triglycerides
    Gaulin, BD; Markowitz, JS; Caley, CF; Nesbitt, LA; Dufresne, RL
  • Olanzapine increases weight and serum triglycerides
    Osser, DO; Najarian, DM; Dufresne, RL
  • Novel antipsychotics and severe hyperlipidemia
    Meyer, JM
  • Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
    Melkersson, KI; Hulting, AL; Brismar, KE
  • Antipsychotic metabolic effects:Weight gain, diabetes mellitus, and lipid abnormalities
    McIntyre, RS; McCann, SM; Kennedy, SH
  • Prevalence and correlates of diabetes in national schizophrenia samples
    Dixon, L; Weiden, P; Delahanty, J; Goldberg, R; Postrado, L; Lucksted, A; Lehman, A
  • The association of medical comorbidity in schizophrenia with poor physical and mental health
    Dixon, L; Postrado, L; Delahanty, J; Fischer, P; Lehman, A
  • Allison DB: Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate
    Fontaine, KR; Heo, M; Harrigan, EP; Shear, CL; Lakshminarayanan, M; Casey, DE
  • Severe hyperglycemia associated with high doses of clozapine letter]
    Kamran, A; Doraiswamy, PM; Jane, JL; Hammett, EB; Dunn, L
  • Diabetic ketoacidosis associated with clozapine treatment [letter]
    Koval, MS; Rames, LJ; Christie, S
  • Lactic acidosis and fatal myocardial failure due to clozapine
    Koren, W; Kreis, Y; Duchowiczny, K; Prince, T; Sancovici, S; Sidi, Y; Gur, H
  • Ketoacidosis as a sideeffect of clozapine: A case report
    Kostakoglu, AE; Yazici, K; Güvener, N
  • Diabetic ketoacidosis from clozapine ad lithium cotreatment [letter]
    Peterson, GA; Byrd, SL
  • Clozapine and associated diabetes mellitus
    Popli, AP; Konicki, PE; Jurjus, GJ; Fuller, MA; Jaskiw, GE
  • Hyperglycemia associated with olanzapine [letter]
    Fertig, MK; Brooks, VG; Shelton, PS
  • Novel antipsychotics and new onset diabetes
    Wirshing, DA; Spellberg, BJ; Erhart, SM; Marder, SR; Wirshing, WC
  • Risperidone-associated new-onset diabetes
    Wirshing, DA; Pierre, JM; Eyeler, J; Weinbach, J; Wirshing, WC
  • Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment
    Thompson, J; Chengappa, KN; Good, CB; Baker, RW; Kiewe, RP; Bezner, J; Schoolder, NR
  • Diabetic ketoacidosis and clozapine
    Ai, D; Roper, TA; Riley, JA
  • Olanzapine-induced ketoacidosis with diabetes mellitus [letter]
    Lindenmayer, JP; Patel, R
  • New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
    Goldstein, LE; Sporn, J; Brown, S
  • Schizophrenia and diabetes mellitus [letter]
    Mohan, D; Gordon, H; Hindley, B; Barker, A
  • New-onset diabetes mellitus associated with the initiation of quetiapine treatment
    Sobel, M; Jaggers, ED; Franz, MA
  • Clozapine-induced diabetic ketacidosis [letter]
    Smith, H; Kenney-Herbert, J; Knowles, L
  • Diabetic ketoacidosis with clozapine treatment [letter]
    Maule, S; Giannella, R; Lanzio, M; Villari, V
  • Diabetic ketoacidosis with olanzapine treatment [letter]
    Gatta, B; Rigalleau, V; Gin, H
  • Hyperglycemia and olanzapine [letter]
    Ober, SK; Hudak, R; Rusterholtz, A
  • Insulin-resistant hyperglycemia induced by clozapine [letter]
    Isakov, I; Klesmer, J; Masand, PS
  • Diabetic ketoacidosis associated with risperidone treatment? [letter]
    Croarkin, PE; Jacobs, KM; Bain, BK
  • New-onset diabetes mellitus associated with quetiapine
    Procyshyn, RM
  • Olanzapine-induced hyperglycemic nonketonic coma
    Roefaro, J; Mukherjee, SM
  • Diabetes as a result of atypical antipsychotic drugs-a report of three cases
    Rigalleau, V; Gatta, B; Bonnaud, S; Masson, M; Bourgeois, ML; Vergnot, V; Gin, H
  • Diabetes mellitus associated with clozapine therapy
    Wehring, H; Alexander, B; Perry, PJ
  • Olanzapine-induced diabetes mellitus
    Bonanno, DG; Davydov, L; Botts, S
  • Diabetic ketoacidosis associated with olanzapine in an adolescent patients
    Selva, KA; Scott, SM
  • The occurence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults
    Westphal, SA
  • Diabetic ketoacidosis in obese African Americans
    Umpierrez, GE; Casals, MM; Gebhart, SP; Mixon, PS; Clark, WS; Phillips, LS
  • Medical comorbidity in schizophrenia
    Jeste, DV; Gladsjo, JA; Lindamer, LA; Lacro, JP
  • Hyperglycemia associated with the use of atypical antipsychotics
    Lindenmayer, JP; Nathan, AM; Smith, RC
  • Relationship of phenothiazine intake and psychiatric diagnosis to glucose level and tolerance
    Efron, HY; Balter, AM
  • Phenothiazines and diabetes in hospitalized women
    Thonnard-Neumann, E
  • Diabetes mellitus in schizophrenic patients
    Mukherjee, S; Decina, P; Bocola, V; Saraceni, F; Scapicchio, P
  • Glucose-insulin metabolism in chronic schizophrenia
    Brambilla, F; Guastalla, A; Guerrini, A; Riggi, F; Rovere, C; Zanoboni, A; Zanoboni-Muciaccia, W
  • Glucose-induced increase inmemoryperformance in patients with schizophrenia
    Newcomer, JW; Craft, S; Fucetola, R; Moldin, SO; Selke, G; Paras, L; Miller, R